ClinicalTrials.gg
CompletedNCT06242678Updated Aug 31, 2026Results posted

Evaluating Spinal Cord Stimulation for Stiff Person Syndrome

An interventional study of SCS trial lead in Stiff-Person Syndrome, sponsored by Wake Forest University Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stiff-Person Syndrome with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Stiff-Person Syndrome · United States.

Enrollment
9th of 10
2 · median 24
Started
2024
with 2 others
No phase
Only one
of the 12
Registered
7th of 12
by date
Lead sponsor
1 of 12
Wake Forest University Health Sciences

Among the 12 studies in Stiff-Person Syndrome with a site in United States, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2024, is the only one with no phase, and was the 7th registered.

Stiff-Person Syndrome

20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.

Browse Stiff-Person Syndrome studies →

Open to participants now

4 of the 12 studies in Stiff-Person Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Stiff-Person Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stiff-Person Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this prospective pilot study is to gather preliminary evidence evaluating spinal cord stimulation (SCS) as a potential therapy for the treatment of rigidity and painful spasms in patients with stiff person syndrome (SPS), a rare autoimmune neurological condition. The hypothesis is that SCS-mediated clinical improvement occurs through multi-modal mechanisms of action targeting several components of neuronal inhibitory signaling pathways in the spinal cord.

Read the detailed description

The hypothesis is that SCS-mediated clinical improvement occurs through multi-modal mechanisms of action targeting several components of neuronal inhibitory signaling pathways in the spinal cord.

03

Conditions studied

  • Stiff-Person Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is 18 years of age or older at the time that the Form (ICF) is signed.
  • Has been clinically diagnosed with stiff person syndrome
  • Has clinical symptoms of muscle rigidity and spasms in the truncal (including abdominal, thoracic paraspinal, and pectoral) or proximal lower limb musculature
  • Has Cerebrospinal fluid (CSF) Anti-glutamic acid decarboxylase 65 (anti-GAD65) antibodies or serum anti-GAD65 antibodies present at any titer
  • Is currently trying or has tried in the past at least two conventional therapies with insufficient symptomatic relief or intolerable side effects (such as nonsteroidal anti- inflammatory drugs, topical patches/creams/gels/ointments, physical therapy, acupuncture, bracing, assistive devices, and lifestyle modification).
  • If taking oral medications, is willing to maintain a stable regimen for the duration of the study period.
  • Is cleared for an implantable medical device by licensed mental health provider.
  • Is an appropriate candidate for the surgical procedures required in this study based on clinical judgement of the study physician.
  • Is willing to and capable of giving written informed consent.
  • Is willing and able to comply with study-related requirements and procedures and attend scheduled visits.

Exclusion criteria

Exclusion criteria:

  • Is less than 18 years of age at the time at the time that the Form (ICF) is signed.
  • Has a (BMI) > 45.
  • Has a history of spine surgery or is planning to receive a spinal injection or procedure while participating in the study, unless this procedure can be postponed until after study completion.
  • Has radiological findings or evidence of moderate to severe central spinal canal stenosis or neuroforaminal stenosis at any thoracic level or laterality.
  • Has radiological findings or evidence of moderate/severe central spinal canal stenosis at any cervical or lumbar level.
  • Has had an epidural injection within 6 weeks of enrollment.
  • Has a history of infection of the spine within 6 months of enrollment.
  • Has received intravenous immunoglobulin therapy within 30 days or is unwilling to maintain a stable regimen (no change in dosage or frequency) during the study period.
  • Has a history of opioid misuse or current chronic opioid therapy.
  • Has evidence of a coagulation abnormality or low count (\<120,000) indicated on Complete Blood Count test at screening, or has a history of abnormal bleeding, or if unable to pause anticoagulation therapy in accordance with accepted guidelines for a spinal cord stimulator trial.
  • Has a current local infection at the anticipated surgical entry site, active systemic infection, or active .
  • Has a medical condition or pain in other area(s) not intended to be treated in this study, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator (such as radicular pain, post-herpetic neuralgia, central canal stenosis of the cervical, thoracic or lumbar spine, critical limb ischemia due to peripheral vascular disease, or small vessel disease).
  • Has a history of untreated major depressive disorder, or history of any mental health disorder with psychotic features, such as schizophrenia.
  • Is pregnant (confirmed via pregnancy test) or plans on becoming pregnant during the study period.
  • Has had, within six months of enrollment, a significant untreated addiction to dependency producing medications, alcohol or illicit drugs.
  • Is concomitantly participating in another interventional clinical trial.
  • Is involved in an injury claim for a study-related chronic pain that is under current litigation.
  • Is a recipient of temporary Social Security Disability Insurance (SSDI) benefits due to study related chronic pain.
  • Has a pending or approved worker's compensation claim for study-related chronic pain.
  • Has low English language literacy interfering with the ability to complete study requirements.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    SCS trial lead

    placement of spinal cord stimulator trial leads

    Device: SCS trial lead

Interventions

  • DeviceSCS trial lead

    placement of spinal cord stimulator trial leads to see if effective in the management of symptoms associated with stiff person syndrome

06

What researchers measure

Primary outcomes

  1. Pain Scores

    baseline pain will be measured on a 0-100 scale, with 100 being the worse level of pain, with improvement in pain level measured immediately prior to removal (kept in up to 10 days), with pain level reassessed at 14 days after trial leads removed to see if returned to baseline

    Time frame: Baseline

  2. Pain Scores

    baseline pain will be measured on a 0-100 scale, with 100 being the worse level of pain, with improvement in pain level measured immediately prior to removal (kept in up to 10 days), with pain level reassessed at 14 days after trial leads removed to see if returned to baseline

    Time frame: Day 24

  3. Michigan Body Map

    The Michigan Body Map (MBM) is a self-report measure to assess body areas of chronic pain with each area of pain marked is scored 1 point. Scores range from 0 to 35, with higher scores indicating more widespread body pain - Maximum score is 35. Higher score denotes more painful areas. It identifies the exact location of the area of recurrent or persistent pain. This map allows for accurate assessment of localized pain and widespread body pain to individualize pain management and track pain progress.

    Time frame: baseline

  4. Michigan Body Map

    The Michigan Body Map (MBM) is a self-report measure to assess body areas of chronic pain with each area of pain marked is scored 1 point. Scores range from 0 to 35, with higher scores indicating more widespread body pain - Maximum score is 35. Higher score denotes more painful areas. It allows a patient to identify the exact location of the area(s) of recurrent or persistent pain. This map allows for accurate assessment of localized pain and widespread body pain to individualize pain management and track pain progress.

    Time frame: up to day 10

  5. Penn Spasm Frequency and Severity Scale

    The first component is a 5 point scale assessing the frequency with which spasms occur ranging from "0 = No spasms" to "4 = Spontaneous spasms occurring more than ten times per hour". The second component is a 3 point scale assessing the severity of spasms ranging from "1 = Mild" to "3 = Severe"

    Time frame: Baseline

  6. Penn Spasm Frequency and Severity Scale

    The first component is a 5 point scale assessing the frequency with which spasms occur ranging from "0 = No spasms" to "4 = Spontaneous spasms occurring more than ten times per hour". The second component is a 3 point scale assessing the severity of spasms ranging from "1 = Mild" to "3 = Severe"

    Time frame: up to day 10

  7. Pain Disability Index

    The Pain Disability Index (PDI) is a self-report questionnaire that measures the impact of pain on a person's life. The PDI is scored on a scale of 0 to 70, with higher scores indicating a greater degree of disability: 0: No disability 10: Total disability The PDI is made up of seven items, each rated on a scale of 0 to 10: Family/home, Recreation, Social activity, Occupation, Sexual behavior, Self-care, and Life-support activity.

    Time frame: Baseline

  8. Pain Disability Index

    The Pain Disability Index (PDI) is a self-report questionnaire that measures the impact of pain on a person's life. The PDI is scored on a scale of 0 to 70, with higher scores indicating a greater degree of disability: 0: No disability 10: Total disability The PDI is made up of seven items, each rated on a scale of 0 to 10: Family/home, Recreation, Social activity, Occupation, Sexual behavior, Self-care, and Life-support activity.

    Time frame: up to Day 10

  9. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is used to evaluate the overall subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Seven components, each of which has a range of 0-3 points. In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. Maximum score is 21, indicative of poor sleep quality. Higher scoring denotes more difficulty in sleep - The global Pittsburgh Sleep Quality Index (PSQI) score ranges from 0 to 21

    Time frame: Baseline

  10. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is used to evaluate the overall subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Seven components, each of which has a range of 0-3 points. In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. Maximum score is 21, indicative of poor sleep quality. Higher scoring denotes more difficulty in sleep - The global Pittsburgh Sleep Quality Index (PSQI) score ranges from 0 to 21

    Time frame: up to Day 10

  11. Fatigue Severity Scale (FSS) Scores

    The FSS is a nine-item questionnaire that uses a seven-point Likert scale to score responses. The scale ranges from 1, which means "strongly disagree," to 7, which means "strongly agree". The minimum score is 9 and the maximum score is 63. A higher score indicates more severe fatigue.

    Time frame: baseline

  12. Fatigue Severity Scale (FSS) Scores

    The FSS is a nine-item questionnaire that uses a seven-point Likert scale to score responses. The scale ranges from 1, which means "strongly disagree," to 7, which means "strongly agree". The minimum score is 9 and the maximum score is 63. A higher score indicates more severe fatigue.

    Time frame: up to day 10

  13. Patient Health Questionnaire-Depression

    The Patient Health Questionnaire-8 (PHQ-8) is a self-reported scale that measures depressive symptoms over the previous two weeks. The PHQ-8 is scored by adding up the scores for each of the eight items, which range from 0 to 3. The response options for each item are: 0: Not at all 1. Several days 2. More than half the days 3. Nearly every day The total score ranges from 0 to 24, with higher scores indicating more severe depressive symptoms. The PHQ-8's scoring categories are: 0-4: No significant depressive symptoms 5-9: Mild symptoms 10-14: Moderate symptoms 15-19: Moderately severe symptoms 20-24: Severe symptoms A score of 10 or higher is considered major depression, and a score of 20 or higher is considered severe major depression

    Time frame: baseline

  14. Patient Health Questionnaire-Depression

    The Patient Health Questionnaire-8 (PHQ-8) is a self-reported scale that measures depressive symptoms over the previous two weeks. The PHQ-8 is scored by adding up the scores for each of the eight items, which range from 0 to 3. The response options for each item are: 0: Not at all 1. Several days 2. More than half the days 3. Nearly every day The total score ranges from 0 to 24, with higher scores indicating more severe depressive symptoms. The PHQ-8's scoring categories are: 0-4: No significant depressive symptoms 5-9: Mild symptoms 10-14: Moderate symptoms 15-19: Moderately severe symptoms 20-24: Severe symptoms A score of 10 or higher is considered major depression, and a score of 20 or higher is considered severe major depression

    Time frame: up to day 10

  15. Generalized Anxiety Disorder

    The GAD-7 is a screening tool that measures the severity of anxiety. It's scored by assigning points to the response categories of "not at all", "several days", "more than half the days", and "nearly every day". The total score ranges from 0 to 21. 0-4: Minimal anxiety, no intervention required 5-9: Mild anxiety, monitoring and follow-up recommended 10-14: Moderate anxiety, education about symptoms and therapy services recommended 15-21: Severe anxiety, therapy and medication recommended

    Time frame: baseline

  16. Generalized Anxiety Disorder

    The GAD-7 is a screening tool that measures the severity of anxiety. It's scored by assigning points to the response categories of "not at all", "several days", "more than half the days", and "nearly every day". The total score ranges from 0 to 21. 0-4: Minimal anxiety, no intervention required 5-9: Mild anxiety, monitoring and follow-up recommended 10-14: Moderate anxiety, education about symptoms and therapy services recommended 15-21: Severe anxiety, therapy and medication recommended

    Time frame: up to day 10

  17. EuroQOL (EQ-5D-5L)

    An index value of 1 represents the best possible health state, while an index value of \<0 (variable) represents the worst possible health state.

    Time frame: Baseline

  18. EuroQOL (EQ-5D-5L)

    An index value of 1 represents the best possible health state, while an index value of \<0 (variable) represents the worst possible health state.

    Time frame: up to Day 10

07

Results

Posted Aug 31, 2026

Participant flow

Participant flow — Overall Study
MilestoneSCS Trial Lead
Started2
Completed2
Not completed0

Outcome measures

PrimaryPain Scores

baseline pain will be measured on a 0-100 scale, with 100 being the worse level of pain, with improvement in pain level measured immediately prior to removal (kept in up to 10 days), with pain level reassessed at 14 days after trial leads removed to see if returned to baseline

Time frame:
Baseline
Reported as:
Mean · score on a scale
Pain Scores
score on a scaleSCS Trial Lead
Pain Scores43.5 ± 21.5
PrimaryPain Scores

baseline pain will be measured on a 0-100 scale, with 100 being the worse level of pain, with improvement in pain level measured immediately prior to removal (kept in up to 10 days), with pain level reassessed at 14 days after trial leads removed to see if returned to baseline

Time frame:
Day 24
Reported as:
Mean · score on a scale
Pain Scores
score on a scaleSCS Trial Lead
Pain Scores25.5 ± 4.5
PrimaryMichigan Body Map

The Michigan Body Map (MBM) is a self-report measure to assess body areas of chronic pain with each area of pain marked is scored 1 point. Scores range from 0 to 35, with higher scores indicating more widespread body pain - Maximum score is 35. Higher score denotes more painful areas. It identifies the exact location of the area of recurrent or persistent pain. This map allows for accurate assessment of localized pain and widespread body pain to individualize pain management and track pain progress.

Time frame:
baseline
Reported as:
Mean · score on a scale
Michigan Body Map
score on a scaleSCS Trial Lead
Michigan Body Map9 ± 6
PrimaryMichigan Body Map

The Michigan Body Map (MBM) is a self-report measure to assess body areas of chronic pain with each area of pain marked is scored 1 point. Scores range from 0 to 35, with higher scores indicating more widespread body pain - Maximum score is 35. Higher score denotes more painful areas. It allows a patient to identify the exact location of the area(s) of recurrent or persistent pain. This map allows for accurate assessment of localized pain and widespread body pain to individualize pain management and track pain progress.

Time frame:
up to day 10
Reported as:
Mean · score on a scale
Michigan Body Map
score on a scaleSCS Trial Lead
Michigan Body Map4 ± 1
PrimaryPenn Spasm Frequency and Severity Scale

The first component is a 5 point scale assessing the frequency with which spasms occur ranging from "0 = No spasms" to "4 = Spontaneous spasms occurring more than ten times per hour". The second component is a 3 point scale assessing the severity of spasms ranging from "1 = Mild" to "3 = Severe"

Time frame:
Baseline
Reported as:
Mean · score on a scale
Penn Spasm Frequency and Severity Scale
score on a scaleSCS Trial Lead
First Component4 ± 0
Second Component3 ± 0
PrimaryPenn Spasm Frequency and Severity Scale

The first component is a 5 point scale assessing the frequency with which spasms occur ranging from "0 = No spasms" to "4 = Spontaneous spasms occurring more than ten times per hour". The second component is a 3 point scale assessing the severity of spasms ranging from "1 = Mild" to "3 = Severe"

Time frame:
up to day 10
Reported as:
Mean · score on a scale
Penn Spasm Frequency and Severity Scale
score on a scaleSCS Trial Lead
First Component2 ± 1
Second Component1.5 ± 0.5
PrimaryPain Disability Index

The Pain Disability Index (PDI) is a self-report questionnaire that measures the impact of pain on a person's life. The PDI is scored on a scale of 0 to 70, with higher scores indicating a greater degree of disability: 0: No disability 10: Total disability The PDI is made up of seven items, each rated on a scale of 0 to 10: Family/home, Recreation, Social activity, Occupation, Sexual behavior, Self-care, and Life-support activity.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Pain Disability Index
score on a scaleSCS Trial Lead
Pain Disability Index40 ± 18
PrimaryPain Disability Index

The Pain Disability Index (PDI) is a self-report questionnaire that measures the impact of pain on a person's life. The PDI is scored on a scale of 0 to 70, with higher scores indicating a greater degree of disability: 0: No disability 10: Total disability The PDI is made up of seven items, each rated on a scale of 0 to 10: Family/home, Recreation, Social activity, Occupation, Sexual behavior, Self-care, and Life-support activity.

Time frame:
up to Day 10
Reported as:
Mean · score on a scale
Pain Disability Index
score on a scaleSCS Trial Lead
Pain Disability Index8.5 ± 8.5
PrimaryPittsburgh Sleep Quality Index (PSQI)

The PSQI is used to evaluate the overall subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Seven components, each of which has a range of 0-3 points. In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. Maximum score is 21, indicative of poor sleep quality. Higher scoring denotes more difficulty in sleep - The global Pittsburgh Sleep Quality Index (PSQI) score ranges from 0 to 21

Time frame:
Baseline
Reported as:
Mean · score on a scale
Pittsburgh Sleep Quality Index (PSQI)
score on a scaleSCS Trial Lead
Pittsburgh Sleep Quality Index (PSQI)6.5 ± 0.5
PrimaryPittsburgh Sleep Quality Index (PSQI)

The PSQI is used to evaluate the overall subjective sleep quality, sleep latency (i.e., how long it takes to fall asleep), sleep duration, habitual sleep efficiency (i.e., the percentage of time in bed that one is asleep), sleep disturbances, use of sleeping medication, and daytime dysfunction. Seven components, each of which has a range of 0-3 points. In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. Maximum score is 21, indicative of poor sleep quality. Higher scoring denotes more difficulty in sleep - The global Pittsburgh Sleep Quality Index (PSQI) score ranges from 0 to 21

Time frame:
up to Day 10
Reported as:
Mean · score on a scale
Pittsburgh Sleep Quality Index (PSQI)
score on a scaleSCS Trial Lead
Pittsburgh Sleep Quality Index (PSQI)6 ± 2
PrimaryFatigue Severity Scale (FSS) Scores

The FSS is a nine-item questionnaire that uses a seven-point Likert scale to score responses. The scale ranges from 1, which means "strongly disagree," to 7, which means "strongly agree". The minimum score is 9 and the maximum score is 63. A higher score indicates more severe fatigue.

Time frame:
baseline
Reported as:
Mean · score on a scale
Fatigue Severity Scale (FSS) Scores
score on a scaleSCS Trial Lead
Fatigue Severity Scale (FSS) Scores44.5 ± 17.5
PrimaryFatigue Severity Scale (FSS) Scores

The FSS is a nine-item questionnaire that uses a seven-point Likert scale to score responses. The scale ranges from 1, which means "strongly disagree," to 7, which means "strongly agree". The minimum score is 9 and the maximum score is 63. A higher score indicates more severe fatigue.

Time frame:
up to day 10
Reported as:
Mean · score on a scale
Fatigue Severity Scale (FSS) Scores
score on a scaleSCS Trial Lead
Fatigue Severity Scale (FSS) Scores29 ± 5
PrimaryPatient Health Questionnaire-Depression

The Patient Health Questionnaire-8 (PHQ-8) is a self-reported scale that measures depressive symptoms over the previous two weeks. The PHQ-8 is scored by adding up the scores for each of the eight items, which range from 0 to 3. The response options for each item are: 0: Not at all 1. Several days 2. More than half the days 3. Nearly every day The total score ranges from 0 to 24, with higher scores indicating more severe depressive symptoms. The PHQ-8's scoring categories are: 0-4: No significant depressive symptoms 5-9: Mild symptoms 10-14: Moderate symptoms 15-19: Moderately severe symptoms 20-24: Severe symptoms A score of 10 or higher is considered major depression, and a score of 20 or higher is considered severe major depression

Time frame:
baseline
Reported as:
Mean · score on a scale
Patient Health Questionnaire-Depression
score on a scaleSCS Trial Lead
Patient Health Questionnaire-Depression7 ± 7
PrimaryPatient Health Questionnaire-Depression

The Patient Health Questionnaire-8 (PHQ-8) is a self-reported scale that measures depressive symptoms over the previous two weeks. The PHQ-8 is scored by adding up the scores for each of the eight items, which range from 0 to 3. The response options for each item are: 0: Not at all 1. Several days 2. More than half the days 3. Nearly every day The total score ranges from 0 to 24, with higher scores indicating more severe depressive symptoms. The PHQ-8's scoring categories are: 0-4: No significant depressive symptoms 5-9: Mild symptoms 10-14: Moderate symptoms 15-19: Moderately severe symptoms 20-24: Severe symptoms A score of 10 or higher is considered major depression, and a score of 20 or higher is considered severe major depression

Time frame:
up to day 10
Reported as:
Mean · score on a scale
Patient Health Questionnaire-Depression
score on a scaleSCS Trial Lead
Patient Health Questionnaire-Depression1 ± 1
PrimaryGeneralized Anxiety Disorder

The GAD-7 is a screening tool that measures the severity of anxiety. It's scored by assigning points to the response categories of "not at all", "several days", "more than half the days", and "nearly every day". The total score ranges from 0 to 21. 0-4: Minimal anxiety, no intervention required 5-9: Mild anxiety, monitoring and follow-up recommended 10-14: Moderate anxiety, education about symptoms and therapy services recommended 15-21: Severe anxiety, therapy and medication recommended

Time frame:
baseline
Reported as:
Mean · score on a scale
Generalized Anxiety Disorder
score on a scaleSCS Trial Lead
Generalized Anxiety Disorder1 ± 0
PrimaryGeneralized Anxiety Disorder

The GAD-7 is a screening tool that measures the severity of anxiety. It's scored by assigning points to the response categories of "not at all", "several days", "more than half the days", and "nearly every day". The total score ranges from 0 to 21. 0-4: Minimal anxiety, no intervention required 5-9: Mild anxiety, monitoring and follow-up recommended 10-14: Moderate anxiety, education about symptoms and therapy services recommended 15-21: Severe anxiety, therapy and medication recommended

Time frame:
up to day 10
Reported as:
Mean · score on a scale
Generalized Anxiety Disorder
score on a scaleSCS Trial Lead
Generalized Anxiety Disorder0.5 ± 0.5
PrimaryEuroQOL (EQ-5D-5L)

An index value of 1 represents the best possible health state, while an index value of \<0 (variable) represents the worst possible health state.

Time frame:
Baseline
Reported as:
Mean · score on a scale
EuroQOL (EQ-5D-5L)
score on a scaleSCS Trial Lead
EuroQOL (EQ-5D-5L)0.4235 ± 0.0115
PrimaryEuroQOL (EQ-5D-5L)

An index value of 1 represents the best possible health state, while an index value of \<0 (variable) represents the worst possible health state.

Time frame:
up to Day 10
Reported as:
Mean · score on a scale
EuroQOL (EQ-5D-5L)
score on a scaleSCS Trial Lead
EuroQOL (EQ-5D-5L)0.78 ± 0.073

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SCS Trial Lead0/2 (0%)0/2 (0%)0/2 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)SCS Trial Lead
Mean66 ± 1
Sex: Female, Male
Sex: Female, Male(Participants)SCS Trial Lead
Female2
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SCS Trial Lead
Hispanic or Latino0
Not Hispanic or Latino2
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SCS Trial Lead
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Atrium Health Wake Forest Baptist
    Winston-Salem, North Carolina 27157, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — study results will be shared via publication

Supporting information: Study protocol

Time frame: after study completion

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Aug 2025, 9 months.

Results were first posted in Aug 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 5, 2024
StartActual
Nov 1, 2024
Primary completionActual
Aug 21, 2025
CompletionActual
Oct 27, 2025
Results first posted
Aug 31, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06242678
Responsible party
Sponsor
First posted
Feb 5, 2024
Start date
Nov 1, 2024
Primary completion
Aug 21, 2025
Completion
Oct 27, 2025
Results posted
Aug 31, 2026
Last update
Aug 31, 2026

Study contacts

Janus S Patel, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion